These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18343999)

  • 1. JAK2V617F mutation in patients with portal vein thrombosis.
    Bayraktar Y; Harmanci O; Büyükasik Y; Shorbagi AI; Sungur AH; Boylu CA; Gürgey A; Balkanci F
    Dig Dis Sci; 2008 Oct; 53(10):2778-83. PubMed ID: 18343999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2V617F mutation in patients with splanchnic vein thrombosis.
    Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
    Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses.
    González-Montero J; Del Valle-Batalla L; Castillo-Astorga R; Marín Valdés A; Conte Lanza G
    Int J Lab Hematol; 2020 Jun; 42(3):331-334. PubMed ID: 32154655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation.
    Naymagon L; Tremblay D; Zubizarreta N; Moshier E; Schiano T; Mascarenhas J
    J Thromb Thrombolysis; 2020 Oct; 50(3):652-660. PubMed ID: 32034618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
    Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
    J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
    Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
    Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease.
    Linnemann B; Kraft C; Roskos M; Zgouras D; Lindhoff-Last E
    Thromb Res; 2012 Jun; 129(6):720-4. PubMed ID: 21982959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis.
    Erkan O; Bozdayi AM; Disibeyaz S; Oguz D; Ozcan M; Bahar K; Karayalcin S; Ozden A; Bozkaya H; Yurdaydin C; Uzunalimoglu O
    Eur J Gastroenterol Hepatol; 2005 Mar; 17(3):339-43. PubMed ID: 15716659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.
    Qi X; Hu F; Yang Z; Han G; Fan D
    Aliment Pharmacol Ther; 2011 Feb; 33(4):495-6; author reply 496-7. PubMed ID: 21235599
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.
    Qi X; Zhang C; Han G; Zhang W; He C; Yin Z; Liu Z; Bai W; Li R; Bai M; Yang Z; Wu K; Fan D
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1036-43. PubMed ID: 22142461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.
    Saugel B; Lee M; Feichtinger S; Hapfelmeier A; Schmid RM; Siveke JT
    J Thromb Thrombolysis; 2015 Jul; 40(1):54-60. PubMed ID: 25115839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
    De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
    Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the presence of hereditary and acquired thrombophilias in Brazilian children and adolescents with diagnoses of portal vein thrombosis.
    Ferri PM; Rodrigues Ferreira A; Fagundes ED; Xavier SG; Dias Ribeiro D; Fernandes AP; Borges KB; Liu SM; de Melo Mdo C; Roquete ML; Penna FJ
    J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):599-604. PubMed ID: 22684349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
    Dong B; Zhang Y; Fu X; Wang G
    Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
    [No Abstract]   [Full Text] [Related]  

  • 17. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
    Kanellopoulou T; Alexopoulou A; Koskinas J
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
    [No Abstract]   [Full Text] [Related]  

  • 18. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
    Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
    Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis.
    Amitrano L; Brancaccio V; Guardascione MA; Margaglione M; Iannaccone L; D'Andrea G; Marmo R; Ames PR; Balzano A
    Hepatology; 2000 Feb; 31(2):345-8. PubMed ID: 10655256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.